Migraine and tension-type headache (TTH) are the most frequent primary headaches and their differentiation is based on strict clinical diagnostic criteria 1 . Though different theories have been formulated to explain these disorders, their physiopathology remains largely unknown.
(sensitization of second-order neurons and somatosensory cortex) mechanisms 4 . Adiponectin (ADP) is a cytokine exclusively secreted by adipocytes that participates in the regulation of glucose and lipids metabolism, and also displays anti-inflammatory properties. Its plasmatic levels are reduced in obesity, insulin resistance, and metabolic syndrome; while its levels were shown to be raised in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease 5 . Chemokines (i.e. chemoattractant cytokine) are a family of small proteins that mediate the migration of leukocytes into inflammatory sites. The family is composed of about 50 related molecules divided into four subfamilies according to the number and spacing of cysteine residues 6 . Neurotrophic factors are polypeptides responsible for neuron survival, axon growth, and the expression of essential proteins for neuronal functioning. Neurotrophic factors are classified in different families, such as the glial cell line-derived neurotrophic factor (GNDF) family and the neurotrophin super-family that includes the brain-derived neurotrophic factor (BDNF), the nervegrouwth factor (NGF), the neurotrophin-3 (NT-3), and the neurotrophin-4/5 (NT-4/5) 7 . Some studies have proposed that pro-and anti-inflammatory molecules may play a role in the pathophysiology of migraine 8,9,10 and TTH 11, 12, 13 . The association between neurotrophic factors and migraine 14, 15, 16 , and neurotrophic factors and TTH 17, 18 has also been investigated. As different pathophysiological mechanisms have been proposed for migraine and TTH, it is possible that the profile of these molecules may be distinct in these two disorders. No previous study has compared these molecules levels in patients with migraine and TTH.
The aim of the current study was to compare ADP, chemokines, and neurotrophic factors serum levels between migraine and TTH patients.
METHOD
We have recently compared ADP, chemokines, and neurotrophic factors between patients with migraine and controls 9, 10, 14, 16 , and between patients with TTH and controls 12, 13, 18 . In the current study we aimed to compare these molecules levels between a group of patients with migraine and a group of patients with TTH.
This was a cross section study including sixty-eight patients with migraine and forty-eight patients with TTH prospectively enrolled from the headache outpatient clinic of the Santa Casa de Misericórdia Hospital, Vitória, Brazil at their first visit to the clinic. All diagnoses were in accordance with the International Classification on Headache Disorders -2 nd edition 19 . The minimal age for the inclusion of patients was 18 years-old. Patients with inflammatory, infectious, autoimmune, and neoplasic diseases were not included in the study, as well as pregnant women and people in use of corticosteroids or immunosuppressant drugs. Demographic (age, ethnicity, and marital status) and headache (time of disease, frequency of attacks in the last month) data were recorded. The Beck Anxiety Inventory (BAI) was used to evaluate the severity of anxiety symptoms, while the Beck Depression Inventory (BDI) the severity of depressive symptoms. Body mass index (BMI), Headache impact test (HIT-6) 20 and allodynia symptom checklist (ASC), with cutaneous allodynia defined as ASC score ≥ 3 21 , were recorded from all subjects. This study received full approval by the Ethics Committee on Research of the "Escola Superior de Ciências da Santa Casa de Vitória", Vitória, Brazil, and informed consent was obtained from each patient.
Whole blood was collected from all the participants, and serum was obtained after centrifugation and kept at -80C until analysis. For analysis we used the same procedures previously described 9, 10, 12, 13, 14, 16, 18 . The assay conditions were controlled, standardized and pre-optimized to ensure repeatability and reproducibility. Analyses were blinded to clinical diagnosis.
Statistical analysis
The data were analyzed with the SPSS, version 15.0 for Windows. The confidence interval was of 95% and the significance level was set at P < 0.05. Verification of normal distribution of data was performed using the Kolmogorov-Smirnov test. Mann-Whitney was used for the medians comparisons of continuous data. Categorical characteristics were compared using chi-square analyses. Binary logistic regression analysis with elimination of nonsignificant covariates was performed with the diagnosis of migraine and TTH as the dependent variables.
RESULTS
Migraine and TTH patients did not differ in age, sex, ethnicity, BMI, marital status, time of disease, and age at headache onset (Table 1) . Migraine patients showed more depressive and anxiety symptoms than TTH patients as assessed by BDI and BAI, respectively (Table 1) . Patients with migraine had higher number of headache days per month, percentage of chronic headache (> 15 headache days per month), headache impact, and percentage of cutaneous allodynia ( Table 1 ). The percentages of migraine and TTH patients with headache at the time of the assessment were not significantly different.
In univariate analysis, a significant difference in CCL11 (chemokine ligand 11)/eotaxin (P = 0.043), CCL24 (chemokine ligand 24)/Eotaxin2 (p = 0.003), CXCL10/IP-10 (chemokine ligand 10/interferon gamma inducible protein-10) (p < 0.001), CCL2/MCP-1 (chemokine ligand 2/ monocyte chemoattractant protein-1) (p = 0.034), CCL3/MIP-1α (chemokine ligand 3/ macrophage inflammatory protein-1 alpha) (p = 0.001), CCL5/RANTES (chemokine ligand 5/regulated on activation, normal T cell expressed and secreted) (p = 0.002), and ADP (p < 0.001) serum levels were found between migraine and TTH ( Table 2) . No significant differences were found in neurotrophic factors levels between migraine and TTH. After adjusted analysis including ASC score, depression and anxiety scores, ADP, chemokines, and neurotropic factors levels as covariates and migraine and TTH as dependent variables we found that the only variables independently associated with the diagnosis (headache x TTH) were cutaneous allodynia (P = 0.035), CCL3/MIP 1α (p = 0.041), CCL5/RANTES (p = 0.013), and ADP (p = 0.017) (Figure) .
DISCUSSION
The current study showed that higher serum levels of CCL3/MIP-1α, CCL5/RANTES, and ADP discriminate migraine patients from TTH patients. CCL-3/MIP-1α is a pro-inflammatory chemokine that participates in acute and chronic inflammatory responses by recruiting T-cells, monocytes, dendritic, and NK cells, playing an important role in the pathogenesis of many inflammatory conditions 22 . CCL-3/MIP-1α also acts as a mediator of chronic pain 23 .
We have previously shown that CCL-3/MIP-1α levels were higher in migraine patients than in subjects without any type of headache disorder 10 , but CCL-3/MIP-1α levels in migraine have not been compared with other headache disorders yet.
CCL5/RANTES is a protein that is chemotactic for T-cells and eosinophils, among other leukocytes 24 . This molecule is also involved in sensory regulation and neuropathic pain 23 . CCL5/RANTES has been previously shown to be higher during migraine attacks 25 , but in the present study this molecule was higher in migraine regardless of presence of pain.
The higher ADP levels in migraine found in the present study are in agreement with some previous studies 9, 10 , although discrepant findings have also been reported 26 
.
The fact that these three molecules were increased in migraine compared with TTH strengthens the hypothesis that inflammatory mechanisms are involved in the pathophysiology of migraine. This finding also supports that different pathophysiological processes underlie these two disorders. It is tempting to speculate that inflammatory molecules may exert a stimulatory effect on the trigeminal vascular system thus enhancing the susceptibility to migraine attacks 27 . Alternatively, these molecules played a role in sensory regulation and sensitization. Our findings are compatible with the latter hypothesis since migraine patients had significantly more cutaneous allodynia, a marker of central sensitization, than patients with TTH 26 . It is possible that the increased production of these molecules affects sensory regulation promoting central sensitization that occurs to a greater extent in migraine than in TTH.
Patients with anxiety and depressive symptoms have higher levels of chemokines 28,29 and ADP
30
. Considering that migraine patients had more depressive and anxiety symptoms than patients with TTH, this could potentially explain the observed elevated levels of CCL-3/MIP-1, CCL5/RANTES, and ADP in migraine. Nevertheless this hypothesis seems unlikely since the results persisted after adjusted analysis with anxiety and depression scores as covariates, suggesting that the higher levels of CCL-3/MIP-1, CCL5/RANTES, and ADP in migraine were not due to the presence of psychiatric comorbidities. It is also unlikely that the found difference was the result of increased frequency and impact of headache in patients with migraine in comparison with TTH.
The limitations of the present study include its crosssectional design, precluding the establishment of causal relationships. Also, we found only a modest difference between ADP and chemokine levels between migraine and TTH with a considerable overlap between these two populations. This undermines the potential role of these molecules as biomarkers of migraine diagnosis. Therefore, larger and prospective studies are still needed to investigate their role as biomarkers. As strengthens of the study it must be mentioned the number of subjects enrolled and the several serum biomarkers measured.
In conclusion, our results suggest that the inflammatory process is involved in the pathophysiology of migraine. The different profile of inflammatory markers can contribute to a better understanding of the pathophysiological boundaries between migraine and TTH. A better knowledge on the molecules involved in primary headache pathogenesis may tailor the development of new and more effective pharmacological strategies for the treatment of these disorders.
